Abstract 171P
Background
To evaluate the prognostic value of prognostic nutritional index(PNI)in esophageal cancer patients under minimally invasive esophagectomy (MIE) with peritoneal metastasis.
Methods
The clinical and pathological data of 197 patients under MIE with anastomotic leakage from January 2013 to December 2015 were analyzed retrospectively.
Results
PNI was not associated with various clinicopathological factors such as age, gender, smoking history, tumor location, tumor length, differentiation degree, T stage, N stage, treatment mode, TNM stage and lymph node metastasis rate (P > 0.05). Univariate survival analysis showed that male, smoking history, advanced tumor stage, tumor length>5cm, advanced N stage, higher lymph node metastasis rate, advanced TNM stage, and treatment modality were associated with poor prognosis. Multivariate analysis showed that N stage (HR = 6.108, CI:1.614-23.113, P = 0.008) and treatment modality (HR = 0.362, CI: 0.213-0.617, P < 0.001) are independent risk factors. PNI is not an independent risk factor.
Conclusions
Prognostic nutritional index is not an independent risk factor of the prognosis for patients under minimally invasive esophagectomy with anastomotic leakage. Treatment method and lymph node metastasis are still the main factors affecting long-term survival in this group.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The 4th Hospital of Hebei Medical University.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
465P - A phase IIIb open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC: Exploratory biomarker analysis
Presenter: Jie Wang
Session: Poster display session
Resources:
Abstract
470P - Prognostic significance of serum biomarkers in small cell lung cancer: A meta-analysis and systematic review
Presenter: Rogelio Velasco
Session: Poster display session
Resources:
Abstract
471P - Chemotherapy in advanced thymic malignancies
Presenter: Ankur Varshney
Session: Poster display session
Resources:
Abstract
466P - Cancer immunotherapy efficacy and patients’ age: A systematic review and meta-analysis
Presenter: Yu Jiang
Session: Poster display session
Resources:
Abstract
506P - Efficacy and safety of pegvorhyaluronidase alfa (PEGPH20; PVHA) and pembrolizumab (pembro) combination therapy in patients (Pts) with stage III/IV non-small cell lung cancer (NSCLC)
Presenter: Jeffrey Ward
Session: Poster display session
Resources:
Abstract
480P - Safety and efficacy of dacomitinib for EGFR+ NSCLC in the subgroup of Asian patients from ARCHER 1050
Presenter: Tony S.K. Mok
Session: Poster display session
Resources:
Abstract
503P - Activity of afatinib in patients (pts) with NSCLC harboring uncommon EGFR mutations: Pooled analysis of three large phase IIIB trials
Presenter: Antonio Passaro
Session: Poster display session
Resources:
Abstract
488P - Randomized trial of prophylactic minocycline for erlotinib-associated skin rash in non-small cell lung cancer (PEARL trial)
Presenter: Kei Kusaka
Session: Poster display session
Resources:
Abstract
495P - Tracking of activating EGFR mutations predicts progression-free survival in advanced EGFR-mutated NSCLC patients treated with osimertinib
Presenter: Anna Buder
Session: Poster display session
Resources:
Abstract
520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
Presenter: Akito Hata
Session: Poster display session
Resources:
Abstract